Halozyme and Oruka sign agreement for Hypercon technology
Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one
Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of Alzheimer’s disease (AD), including the clinical progression of its lead candidate, GSM-779690T.